Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Assessment of the Effectiveness of Niclosamide as Add on Therapy to the Standard of care Measures in COVID-19 Management in a randomized controlled clinical trial
Protocol of therapy Niclosamaide Add on group
Control group The patients in this group will receive only standard care which will include all or some of the following, according to the clinical condition of each patient:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Niclosamide group: NCS group | Experimental | NCL + standard therapy |
|
| Control group | No Intervention | Control group |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Niclosamide Oral Tablet | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Cure of the patient | To assess the percentage of cure of the patient and evaluated by normalization of clinical evaluation, laboratory investigations, and imaging. | 7 days |
| Time to recovery | - to study the time to recovery ( stay days in hospital) | 7 days |
| Measure | Description | Time Frame |
|---|---|---|
| The percentage of Progressive patients | - T assess percentage of progressive patients to more advanced disease | 7 days |
| Rate of mortality | - To evaluate mortality rate among NCS add on group compared to controls |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Faiq I. Gorial, Professor | Contact | 009647801730696 | faiqig@yahoo.com |
| Name | Affiliation | Role |
|---|---|---|
| Ahmed S Abdulamir, Professor | College of Medicine-Al-Nahrain University | Principal Investigator |
| Faiq I. Gorial, Prof | College of Medicine-University of Baghdad | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ahmed S. Abdulamir | Recruiting | Baghdad | Baghdada | 00964 | Iraq |
All collected IPD, all IPD that underlie results in a publication
Not provided
6 months after publication
Will be given by the principle investgator
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Sep 12, 2021 | |
| Reset | Sep 16, 2021 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Sep 12, 2021 | Sep 16, 2021 |
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D009534 | Niclosamide |
| ID | Term |
|---|---|
| D012458 | Salicylanilides |
| D000813 | Anilides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| 7 days |
| Side effects | - To demonstrate side effects seen during the trial and will be assessed according clinical evaluation and the appropriate laboratory investigation. | 7 days |
| Manal K abdulrrazaq, Professor |
| College of Medicine-University of Baghdad |
| Study Chair |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D012457 |
| Salicylamides |
| D000814 | Aniline Compounds |
| D000588 | Amines |